Nls Pharmaceutics Ag Stock Analysis

NLS Stock Analysis Notes

About 41.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 6.74. NLS Pharmaceutics had not issued any dividends in recent years. The entity had 1:40 split on the 27th of September 2024. NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company was incorporated in 2015 and is based in Zurich, Switzerland. Nls Pharmaceutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To find out more about NLS Pharmaceutics AG contact Alexander MBA at 41 44 512 21 50 or learn more at https://nlspharma.com.

NLS Pharmaceutics Investment Alerts

NLS Pharmaceutics Upcoming and Recent Events

NLS Stock Institutional Investors

Note, although NLS Pharmaceutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

NLS Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.13 M.

NLS Profitablity

Management Efficiency

NLS Pharmaceutics has return on total asset (ROA) of (2.2776) % which means that it has lost $2.2776 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.6292) %, meaning that it created substantial loss on money invested by shareholders. NLS Pharmaceutics' management efficiency ratios could be used to measure how well NLS Pharmaceutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NLS Pharmaceutics' Return On Capital Employed is relatively stable compared to the past year. As of 03/26/2025, Return On Equity is likely to grow to 1.66, though Return On Tangible Assets are likely to grow to (7.20). As of 03/26/2025, Total Current Liabilities is likely to grow to about 9.6 M. Also, Liabilities And Stockholders Equity is likely to grow to about 3.3 M

Technical Drivers

As of the 26th of March, NLS Pharmaceutics secures the Risk Adjusted Performance of 0.0217, market risk adjusted performance of 0.6106, and Mean Deviation of 5.74. In respect to fundamental indicators, the technical analysis model lets you check practical technical drivers of NLS Pharmaceutics, as well as the relationship between them.

NLS Pharmaceutics Price Movement Analysis

NLS Pharmaceutics Outstanding Bonds

NLS Pharmaceutics Predictive Daily Indicators

NLS Pharmaceutics Forecast Models

NLS Pharmaceutics' time-series forecasting models are one of many NLS Pharmaceutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NLS Pharmaceutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how NLS Pharmaceutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NLS shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NLS Pharmaceutics. By using and applying NLS Stock analysis, traders can create a robust methodology for identifying NLS entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. NLS analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. NLS analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

NLS Pharmaceutics AG stock analysis indicators help investors evaluate how NLS Pharmaceutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading NLS Pharmaceutics shares will generate the highest return on investment. By understating and applying NLS Pharmaceutics stock analysis, traders can identify NLS Pharmaceutics position entry and exit signals to maximize returns.

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.